---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-058415"
form_type: "8-K"
ticker: null
cik: "0001012477"
company_name: "AVADEL PHARMACEUTICALS PLC"
filed_at: "2024-05-08T23:59:59+00:00"
generated_at: "2026-06-02T08:24:37.805639+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Avadel reports Q1 LUMRYZ revenue $27.2M; patient starts up 70%; pediatric sNDA accepted

## Summary
- Q1 2024 net product revenue of $27.2M from LUMRYZ; gross profit $25.7M.
- Net loss narrowed to $27.3M ($0.30 per share) vs. $30.8M ($0.48) in Q1 2023.
- Over 1,700 patients initiated therapy (up >70% from Dec 31); RYZUP enrollments 2,800 (up ~50%).
- FDA accepted sNDA for LUMRYZ in pediatric narcolepsy; PDUFA date set for Sept 7, 2024.
- On track to enroll first patient in Phase 3 idiopathic hypersomnia trial in H2 2024.

## SEC filing metadata
- accession: 0001104659-24-058415
- form_type: 8-K
- cik: 0001012477
- company_name: AVADEL PHARMACEUTICALS PLC
- filed_at: 2024-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1012477/000110465924058415/0001104659-24-058415-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1012477/000110465924058415/tm2413641d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-058415
- JSON: https://secwatch.observer/filing/0001104659-24-058415.json
- Plain text: https://secwatch.observer/filing/0001104659-24-058415.txt

## Key facts
- Earnings Releases
  AVADEL PHARMACEUTICALS PLC reported the quarter ended March 31, 2024 results: revenue $27.2 million, net income $27.3 million, EPS ($0.30) per diluted share.
  - Period: the quarter ended March 31, 2024
  - Revenue: $27.2 million
  - Net income: $27.3 million
  - EPS: ($0.30) per diluted share
  - Result: reported results
  source text: --- EX-99.1 2 tm2413641d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Avadel Pharmaceuticals Provides Corporate Update and Reports First Quarter 2024 Financial Results -- Generated $27.2 million in net revenue from sales of LUMRYZTM -- -- Through March 31, greater than 2,800 patients enrolled in Avadel’s RYZUP patient support services and more than 1,700 patients
  evidence_url: https://www.sec.gov/Archives/edgar/data/1012477/000110465924058415/0001104659-24-058415-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.